UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 01/2019, Volume 321, Issue 3, pp. 277 - 287
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Primary Prevention | Cardiovascular Diseases - prevention & control | Humans | Diabetes Mellitus - drug therapy | Male | Risk | Aspirin - adverse effects | Female | Aspirin - therapeutic use | Hemorrhage - chemically induced | Platelet Aggregation Inhibitors - therapeutic use | Diabetes Complications - prevention & control | Platelet Aggregation Inhibitors - adverse effects | Treatment outcome | Aspirin | Usage | Control | Analysis | Cardiovascular diseases | Risk factors | Myocardial infarction | Cerebral infarction | Medical research | Stroke | Diabetes mellitus | Health risks | Clinical trials | Risk reduction | Cardiovascular disease | Systematic review | Hemorrhage | Bleeding | Disease prevention | Prevention | Correlation analysis | Infarction | Risk management | Bayesian analysis | Index Medicus | Abridged Index Medicus | Original Investigation | Research
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2019, Volume 73, Issue 22, pp. 2791 - 2802
icosapent ethyl | eicosapentaenoic acid | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Hypertriglyceridemia - drug therapy | Recurrence | Double-Blind Method | Follow-Up Studies | Eicosapentaenoic Acid - analogs & derivatives | Humans | Middle Aged | Risk Factors | Eicosapentaenoic Acid - adverse effects | Hypercholesterolemia - mortality | Male | Survival Rate | Hypercholesterolemia - drug therapy | Myocardial Ischemia - drug therapy | Hypertriglyceridemia - complications | Hypertriglyceridemia - mortality | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Female | Hypercholesterolemia - complications | Aged | Eicosapentaenoic Acid - therapeutic use | Myocardial Ischemia - mortality | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Myocardial infarction | Intervention | Heart attacks | Angina | Confidence intervals | Prevention | Reduction | Ischemia | Atherosclerosis | Mathematical models | Statins | Cerebral infarction | Stroke | Statistical analysis | Diabetes mellitus | Mortality | Health risks | Triglycerides | Regression analysis | Angina pectoris | Patients | Cholesterol | Studies | Statistical models | Arteriosclerosis | Biomarkers | Death | Diabetes | Cardiovascular diseases | Median (statistics) | Health risk assessment
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2018, Volume 71, Issue 23, pp. 2628 - 2639
heart failure | diabetes mellitus | sodium glucose cotransporter-2 inhibitors | death | observational studies | SGLT-2 inhibitor | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Hypoglycemic Agents - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Sodium-Glucose Transporter 2 Inhibitors - pharmacology | Male | Diabetes Mellitus, Type 2 - epidemiology | Hypoglycemic Agents - pharmacology | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Internationality | Cardiovascular Diseases - blood | Cardiovascular Diseases - epidemiology | Adult | Female | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Electronic Health Records | Cohort Studies | Heart | Drugs | Laboratories | Identification methods | Personal health | Clinical trials | Medical records | Glucose | Subgroups | Matching | Confidence intervals | Databases | Risk assessment | Diuretics | Population | Diabetes mellitus (non-insulin dependent) | Heart diseases | Heart failure | Health insurance | Stroke | Payment systems | Diabetes mellitus | Mortality | Health risks | Patients | Prescription drugs | Hospitals | Inhibitors | Sodium | Death | Diabetes | Clinical medicine | Cardiovascular diseases | Pharmaceuticals
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 01/2011, Volume 57, Issue 3, pp. 292 - 299
mortality | sedentary behavior | physical activity | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Cardiology. Vascular system | Biological and medical sciences | Medical sciences | Body Mass Index | Leisure Activities | Cardiovascular Diseases - etiology | Follow-Up Studies | Cholesterol - blood | Humans | Middle Aged | Mortality | Risk Factors | Male | Sedentary Lifestyle | Biomarkers - blood | Video Games - adverse effects | C-Reactive Protein - metabolism | Health Surveys - methods | Television | Time Factors | Cardiovascular Diseases - blood | Cardiovascular Diseases - mortality | Adult | Female | Aged | Population Surveillance - methods | Body mass index | Physical fitness | Heart attacks | Health risk assessment | Index Medicus | Abridged Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 03/2010, Volume 55, Issue 13, pp. 1318 - 1327
arterial stiffness | meta-analysis | prediction | cardiovascular risk | pulse wave velocity | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Aorta - pathology | Cardiovascular Diseases - physiopathology | Pulsatile Flow - physiology | Risk Assessment | Humans | Cardiovascular Diseases - mortality | Elasticity | Aorta - physiopathology | Vascular Resistance - physiology | Hypertension | Stroke | Heart attacks | Mortality | Bias | Cardiovascular disease | Estimates | Studies | Confidence intervals | Body mass index | Population | Diabetes | Kidney diseases | Drug therapy | Pressure transducers | Age | Index Medicus | Abridged Index Medicus
Journal Article
Vaccine, ISSN 0264-410X, 2014, Volume 32, Issue 37, pp. 4758 - 4765
Allergy and Immunology | Myocarditis | ACAM2000 | Pericarditis | Ischemic cardiac events | Myo/pericarditis | Immunology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Fundamental and applied biological sciences. Psychology | Biological and medical sciences | Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) | Microbiology | Applied microbiology | Myocardial Infarction - epidemiology | Laboratory Personnel | Military Personnel | Adverse Drug Reaction Reporting Systems | Humans | Middle Aged | Male | Vaccination - adverse effects | Young Adult | Adult | Female | Smallpox Vaccine - adverse effects | Myocardial Ischemia - epidemiology | Smallpox | Cardiovascular disease | Immunization | Heart attacks | Vaccines | Index Medicus | ischemic cardiac events | myo | pericarditis | myocarditis
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2011, Volume 57, Issue 16, pp. 1666 - 1675
Cardiovascular | Internal Medicine | rosuvastatin | low-density lipoprotein cholesterol | cardiovascular risk | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Complications and side effects | Rosuvastatin | Low density lipoproteins | Cholesterol | Cardiovascular agents | Antilipemic agents
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 05/2018, Volume 71, Issue 20, pp. 2306 - 2315
amputation | peripheral artery disease | antithrombotic therapy | death | major adverse limb events | Double-Blind Method | Follow-Up Studies | Humans | Middle Aged | Peripheral Arterial Disease - drug therapy | Lower Extremity - pathology | Male | Mortality - trends | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Peripheral Arterial Disease - mortality | Peripheral Arterial Disease - diagnosis | Platelet Aggregation Inhibitors - administration & dosage | Female | Aged | Drug Therapy, Combination | Lower Extremity - blood supply | Intervention | Anticoagulants | Stroke | Prognosis | Complications | Heart surgery | Angioplasty | Mortality | Health risks | Risk | Cardiovascular disease | Hospitalization | Patients | Incidence | Vascular diseases | Ischemia | Coronary vessels | Amputation | Cardiovascular diseases
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2017, Volume 69, Issue 25, pp. 3015 - 3026
vascular events | elderly | primordial prevention | cardiovascular health | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Risk Assessment - methods | France - epidemiology | Prevalence | Prospective Studies | Survival Rate - trends | Follow-Up Studies | Humans | Risk Factors | Male | Time Factors | Cardiovascular Diseases - epidemiology | Female | Aged | Health Status | Stroke (Disease) | Medical research | Comorbidity | Analysis | Mortality | Chronic diseases | Medicine, Experimental | Health aspects | Coronary heart disease | Prevalence studies (Epidemiology) | Heart | Stroke | Communities | Categories | Cardiovascular disease | Multivariate analysis | Risk analysis | Patients | Coronary artery disease | Diseases | Older people | Health hazards | Men | Aging | Fatalities | Cardiovascular diseases | Cardiology | Health risk assessment | Heart diseases | Age | Geriatrics | Index Medicus | Abridged Index Medicus | Life Sciences | Santé publique et épidémiologie
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 02/2019, Volume 73, Issue 4, pp. 387 - 396
alirocumab | total events | acute coronary syndrome | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Acute Coronary Syndrome - drug therapy | Antibodies, Monoclonal, Humanized | Follow-Up Studies | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Middle Aged | Antibodies, Monoclonal - therapeutic use | Female | Male | Aged | Drug Therapy, Combination | Myocardial infarction | Heart | Heart attacks | Risk | Cardiovascular disease | Family medical history | Angina | Confidence intervals | Heterogeneity | Ischemia | Frailty | Heart diseases | Statins | Cerebral infarction | Stroke | Mortality | Hospitalization | Angina pectoris | Estimates | Patients | Health hazards | Death | Fatalities | Infarction | Diabetes | Acute coronary syndromes | Health risk assessment
Journal Article